Table 1.
Patient characteristics
| Total N = 70 | ||
|---|---|---|
| Age | Median years (range) | 56 (26-77) |
| Sex | Male, n (%) | 44 (62.9) |
| Female, n (%) | 26 (37.1) | |
| ECOG | 0, N (%) | 7 (10) |
| 1, N (%) | 57 (81.4) | |
| 2, N (%) | 6 (8.6) | |
| Palliative setting | Metastatic, N (%) | 56 (80) |
| Recurrent, N (%) | 14 (20) | |
| HER2 | Negative, N (%) | 62 (88.6) |
| Positive, N (%) | 8 (11.4) | |
| Tumor location | Stomach, N (%) | 65 (92.9) |
| GEJ, N (%) | 5 (7.1) | |
| Pathology | Adenocarcinoma, N (%) | 56 (80.0) |
| (pure) PCC, N (%) | 13 (18.6) | |
| Others, N (%)* | 1 (1.4) | |
| SRC component | No, N (%) | 48 (68.6) |
| Yes, N (%) | 22 (31.4) | |
| Lauren | Intestinal, N (%) | 9 (12.9) |
| Diffuse, N (%) | 16 (22.9) | |
| Mixed, N (%) | 1 (1.4) | |
| Unknown, N (%)† | 44 (62.9) | |
| Chemotherapy regimen | FOLFOX, N (%) | 40 (57.1) |
| XP, N (%) | 28 (40.0) | |
| Others, N (%)‡ | 2 (2.9) | |
| Overall Survival | Median months (95% CI) | 12.5 (10.1-17) |
| Progression-free Survival | Median months (95% CI) | 6 (4.3-6.9) |
| Follow-up duration | Median months (range) | 81.6 (32.6-113) |
*
Adenosquamous carcinoma.
†
Lauren classification: not evaluable in 44 out of 70, due to small amount of tissue.
‡
One patient in the HER2-positive group was treated with trastuzumab plus conventional chemotherapy, another patient was treated with irinotecan, 5-fluorouracil, and leucovorin.
Abbreviation: ECOG, Eastern Cooperative Group performance status; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; PCC, poorly cohesive carcinoma; SRC, signet ring cell; FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; XP, capecitabine and cisplatin.